Novel COX-2 Inhibitor for Breast Cancer Therapy
Abstract
Recent studies have shown that NSAIDS such as aspirin reduce the incidence of human cancers by inhibiting the enzyme Cyclooxygenase (COX), which plays a key role in arachidonic acid metabolism. It is now known that COX exists in at leas two isoforms, term COX-l and COX-2. Of these, COX-2 has also been found to be constitutively expressed in a number of tumor tissues, including breast. The purpose of out study to develop new COX-2 inhibitors that can be sued in breast cancer therapy. We have exploited the structural differences between the two COX enzymes to develop specific inhibitors of COX-2 and have identified three classes of novel COX-2 inhibitors that possess tumor growth inhibitory activity. Some of these compounds inhibit growth of both COX-2 positive as well as COX-2 negative tumor cell lines, suggesting that these compounds might target another protein that plays an important role n the growth of tumor cells. These studies suggest that these compounds may play an important role as an anti-cancer and chemopreventive agents.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA420352
Entities
People
- E. Premkumar Reddy
Organizations
- Temple University